Milnacipran
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Milnacipran: Migraine disorder
One-Sentence Summary
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI), originally used to treat fibromyalgia and myofascial pain syndrome. The TxGNN model predicts it may be effective for migraine disorder, with 2 clinical trials and 5 publications currently supporting this direction, mostly small, early-stage or open-label studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (11 of 11) – CDSCO approval status is not included in this data |
| Number of Listed Products | 11 (valid: 11) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, milnacipran is an SNRI, its use in fibromyalgia is established, and mechanistically it may be applicable to migraine.
Other SNRIs and tricyclic antidepressants with serotonergic and noradrenergic activity are used for migraine prevention. Descending pain-modulatory pathways are implicated in both fibromyalgia and migraine, so the mechanistic link is plausible. However, this link rests on the known drug class rather than on a documented mechanism record for milnacipran itself.
The prediction should be treated as a research hypothesis. The other predicted indications (such as migraine with brainstem aura, tendinitis, myositis variants and cauda equina syndrome) have no trials or literature. Their high scores likely reflect ontology proximity or model artifacts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01393522 | NA | Completed | 37 | Randomized, double-blind, placebo-controlled trial of twice-daily milnacipran for migraine headache pain (2011–2013). No results in the compiled data. |
| NCT01319825 | Phase 4 | Unknown | 45 | Open-label pilot study of milnacipran to reduce headache frequency in episodic and chronic migraine (2011–2012). Likely the registration of the published study PMID 24030685. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24030685 | 2014 | Prospective open-label study | Neurological Sciences | 3-month pilot in 38 episodic and 7 chronic migraine patients using headache diaries, prompted by clinical observation that milnacipran reduced migraine headaches. |
| 26798881 | 2015 | Review | J Calif Dent Assoc | Review of chronic orofacial pain treatments. SNRIs are among the options for neuropathic pain, and the three drugs approved for fibromyalgia, including milnacipran, are described as not robust. |
| 21377931 | 2011 | Review | Curr Opin Pharmacol | Overview of 5-HT receptor ligands in pain. It notes that serotonin/noradrenaline reuptake inhibitors may act through 5-HT-modulated analgesia. |
| 22967190 | 2012 | Pharmacovigilance analysis | Drug Safety | Analysis of competition bias in safety signal detection in French spontaneous reports. Not directly about efficacy. |
| 31804357 | 2019 | Case report | Medicine | Reversible cerebral vasoconstriction with thunderclap headache, which is hard to distinguish from migraine. Likely a safety signal. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 137396 | Milnace 25 Tablet (Torrent Pharmaceuticals Ltd) | Strip of 10 tablets | Not stated |
| 137660 | Milnace 50 Tablet (Torrent Pharmaceuticals Ltd) | Strip of 10 tablets | Not stated |
| 137571 | Milza 25 Capsule (Intas Pharmaceuticals Ltd) | Strip of 10 capsules | Not stated |
| 137928 | Milza 50mg Capsule (Intas Pharmaceuticals Ltd) | Strip of 10 capsules | Not stated |
| 146441 | Milpran 25mg Capsule (Ajanta Pharma Ltd) | Strip of 10 capsules | Not stated |
All 11 registrations are valid single-ingredient products. None has been cancelled.
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): hypertension and hypertensive disorder, cardiovascular and heart disease, epilepsy, liver disease, gallbladder disease, substance abuse/dependence, blood coagulation disease, angle-closure (closed-angle) glaucoma, inappropriate ADH syndrome (including the nephrogenic form), serotonin syndrome, and urinary tract obstruction.
- Drug Interactions: 144 interactions were recorded. Major-level interactions include bupropion, lorcaserin, diethylpropion, phentermine, dexfenfluramine, dolasetron and palonosetron. Examples of moderate-level interactions are acetylsalicylic acid, morphine, epinephrine, ephedrine, naltrexone and metoclopramide.
- Other signals: one case report in the literature describes reversible cerebral vasoconstriction with thunderclap headache, which may be a safety signal worth monitoring in a migraine population.
Package insert warnings and contraindications were not available, so please refer to the package insert for the complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link is plausible and two migraine-specific studies exist, but both are small (37 and 45 patients), and one is open-label and uncontrolled. The randomized trial has no available results, and no Phase 3 evidence exists. Evidence is therefore early and best treated as a research question rather than a basis for clinical or regulatory action.
To proceed, the following is needed:
- Results of the randomized placebo-controlled trial NCT01393522, and the full outcome data of the open-label study (PMID 24030685)
- Package insert warnings and contraindications from Indian labels (currently blocking safety screening)
- Mechanism-of-action data from DrugBank
- A safety review for migraine patients, particularly cardiovascular and blood pressure risks, and the reported cerebral vasoconstriction signal
- If results are encouraging, an adequately powered controlled trial in migraine prevention
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.